A population-based study on the effect of a routine second-look resection on survival in primary stage T1 bladder cancerShow others and affiliations
2021 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 55, no 2, p. 108-115Article in journal (Refereed) Published
Abstract [en]
Objective To assess the value of second-look resection (SLR) in stage T1 bladder cancer (BCa) with respect to progression-free survival (PFS), and also the secondary outcomes recurrence-free survival (RFS), bladder-cancer-specific survival (CSS), and cystectomy-free survival (CFS). Patients and methods The study included 2456 patients diagnosed with stage T1 BCa 2004-2009 with 5-yr follow-up registration in the nationwide Bladder Cancer Data Base Sweden (BladderBaSe). PFS, RFS, CSS, and CFS were evaluated in stage T1 BCa patients with or without routine SLR, using univariate and multivariable Cox regression with adjustment for multiple confounders (age, gender, tumour grade, intravesical treatment, hospital volume, comorbidity, and educational level). Results SLR was performed in 642 (26%) individuals, and more frequently on patients who were aged < 75 yr, had grade 3 tumours, and had less comorbidity. There was no association between SLR and PFS (hazard ratio [HR] 1.1, confidence interval [CI] 0.85-1.3), RFS (HR 1.0, CI 0.90-1.2), CFS (HR 1.2, CI 0.95-1.5) or CSS (HR 1.1, CI 0.89-1.4). Conclusions We found similar survival outcomes in patients with and patients without SLR, but our study is likely affected by selection mechanisms. A randomised study defining the role of SLR in stage T1 BCa would be highly relevant to guide current praxis.
Place, publisher, year, edition, pages
Taylor & Francis, 2021. Vol. 55, no 2, p. 108-115
Keywords [en]
Bladder cancer; transurethral resection; second look resection; T1
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-174863DOI: 10.1080/21681805.2021.1892179ISI: 000626037300001PubMedID: 33678124OAI: oai:DiVA.org:liu-174863DiVA, id: diva2:1542661
Note
Funding Agencies|Swedish Cancer SocietySwedish Cancer Society [CAN 2019/62, CAN 2017/278]; Lund Medical Faculty (ALF); Skane University Hospital Research Funds; Gyllenstierna Krapperups Foundation; Cancer Research Fund at Malmo General Hospital; Stiftelsen Sigurd och Elsa Goljes Minne; Bergqvist Foundation; Skane County Councils Research and Development Foundation [REGSKANE622351]; Gosta Jonsson Research Foundation; Foundation of Urological Research; Hillevi Fries Research Foundation
2021-04-082021-04-082025-02-18Bibliographically approved